Skip to main content
Intended for healthcare professionals
[image]
•  Subscribe
•  Log In More
Log in via Institution
Log in via OpenAthens
Log in via BCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username *
Password *
Forgot your log in details?Register a new account?
Forgot your user name or password?
•  Basket
•  Search More
Search for this keyword
Advanced search
[image]
•  Latest content
•  Current issue
•  Archive
•  Browse by collection
•  Authors
•  About
•  Podcasts
Search for this keyword


Advanced search
•  Close More
Main menu
○  Latest content
○  Current issue
○  Archive
○  Browse by collection
○  Authors
○  About
○  Podcasts
•  Subscribe
•  Log in More
Log in via Institution
Log in via OpenAthens
Log in via BCS
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username *
Password *
Forgot your log in details?Register a new account?
Forgot your user name or password?
•  BMJ Journals
You are here
•  Home
•  Archive
•  Volume 107, Issue 2


•  Risk of severe COVID-19 disease with ACE inhibitors and
angiotensin receptor blockers: cohort study including 8.3
million people
Email alerts
Article Text
Article menu
•  Article
Text
•  Article
info
•  Citation
Tools
•  Share
•  Rapid Responses
•  Article
metrics
•  Alerts
[image]PDF
Correspondence
Risk of severe COVID-19 disease with ACE inhibitors and angiotensin
receptor blockers: cohort study including 8.3 million people
1. http://orcid.org/0000-0002-2479-7283Julia Hippisley-Cox1,
2. Pui San Tan1,
3. Carol Coupland2
1. 1 Nuffield Department of Primary Care Health Sciences,
University of Oxford, Oxford, UK
2. 2 Division of Primary Care, School of Medicine, University of
Nottingham, Nottingham, UK
1. Correspondence to Dr Julia Hippisley-Cox, Primary Care
Health Sciences, Oxford University, Oxford OX1 2JD, UK;
Julia.Hippisley-Cox{at}phc.ox.ac.uk


https://doi.org/10.1136/heartjnl-2020-318312
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link
below which will take you to the Copyright Clearance Center’s
RightsLink service. You will be able to get a quick price and instant
permission to reuse the content in many different ways.
•  electronic health records
•  drug monitoring
The Authors’ reply
We thank interested readers and their interesting views and
opinions on our recently published study ‘Risk of severe COVID-19
disease with ACE inhibitors and angiotensin receptor blockers:
cohort study including 8.3 million people’.1 Please find our
responses to views and comments as follows.
In this study, the most recent smoking records available from
general practices were used prior to cohort entry. Smoking status
was recorded for 96% of patients included in the study, although
recent changes in smoking status might not have been recorded. At
the point of analyses of the study, negative test results were not yet
available from Public Health England (PHE). However, we agree
that it will be useful to compare clinical and demographic
characteristics between COVID-19 positive and negative test …
View Full Text
Footnotes


•  Twitter @juliahcox
•  Contributors All authors contributed to this reply to
reviewers.
•  Funding This study was funded by John Fell Oxford
University Press Research Fund, Wellcome Trust (221514/
Z/20/Z), Oxford Wellcome Institutional Strategic Support
Fund (204826/Z/16/Z) and Cancer Research UK (C5255/
A18085).
•  Competing interests JH-C reports grants from the National
Institute for Health Research Biomedical Research Centre,
Oxford, grants from John Fell Oxford University Press
Research Fund, grants from Cancer Research UK (CRUK)
grant number C5255/A18085, through the Cancer Research
UK Oxford Centre, and grants from the Oxford Wellcome
Institutional Strategic Support Fund (204826/Z/16/Z), during
the conduct of the study; personal fees and other from
ClinRisk (until 2019), outside the submitted work; and is an
unpaid director of QResearch, a not-for-profit organisation
which is a partnership between the University of Oxford and
EMIS Health, which supply the QResearch database used for
this work. PST reports consulting with AstraZeneca and Duke-
NUS, outside the submitted work. CC has nothing to disclose.
•  Patient and public involvement Patients and/or the public
were not involved in the design, or conduct, or reporting, or
dissemination plans of this research.
•  Patient consent for publication Not required.
•  Provenance and peer review Commissioned; internally peer
reviewed.
Linked Articles
•  Correspondence
Risk of COVID-19 and smoking
Ivan Berlin


Heart 2020; 107 170-170 Published Online First: 04 Nov
2020. doi: 10.1136/heartjnl-2020-318311
Read the full text or download the PDF:
Subscribe
Log in 


Log in via Institution
Log in via OpenAthens
Log in via BCS
Log in using your username and password


For personal accounts OR managers of institutional accounts
Username *
Password *
Forgot your log in details?Register a new account?
Forgot your user name or password?
Read the full text or download the PDF:
Subscribe
Log in 


Log in via Institution
Log in via OpenAthens
Log in via BCS
Log in using your username and password


For personal accounts OR managers of institutional accounts
Username *
Password *
Forgot your log in details?Register a new account?
Forgot your user name or password?


•  [image]
•  Content


○  Latest content
○  Current issue
○  Archive
○  Browse by collection
○  Most read articles
○  Top cited articles
○  Responses
•  Journal
○  About
○  Editorial board
○  Sign up for email alerts
○  Subscribe
○  Education in heart
○  Best Research Paper Award
○  Thank you to our reviewers
•  Authors
○  Instructions for authors
○  Submit an article
○  Editorial policies
○  Open Access at BMJ
○  BMJ Author Hub
•  Help
○  Contact us
○  Reprints
○  Permissions
○  Advertising
○  Feedback form
•  RSS
•  Twitter
•  Facebook
•  SoundCloud
•  YouTube


•  Website Terms & Conditions
•  Privacy & Cookies
•  Contact BMJ
Cookie Settings
Online ISSN: 1468-201XPrint ISSN: 1355-6037


Copyright © 2025 BMJ Publishing Group Ltd & British Cardiovascular Society. All
rights, including for text and data mining, AI training, and similar technologies,
are reserved.


